Bioactivx raises $3M for synthetic wound-care technology in Singapore
What's the deal? BioactivxDealroom has a profile for this one. Try Dealroom →, a Singapore-based deep-tech startup spun off from A*STARDealroom has a profile for this one. Try Dealroom → and SingHealthDealroom has a profile for this one. Try Dealroom →, has raised $3 million in a Series A round. It was co-led by Martin Krupp, managing director of Swiss family office ContInvest, and Singapore venture capital firm Cocoon CapitalDealroom has a profile for this one. Try Dealroom →.
What's the endgame? The company is developing Bioactiv® Matrix, a synthetic wound-care technology. Skin substitutes can support healing in chronic wounds by temporarily or permanently replacing damaged skin.
Where's the money going? Proceeds will expand manufacturing in Singapore, strengthen the commercial and regulatory teams, and fund post-market clinical trials for Bioactiv® Matrix. The startup also plans to advance other wound-care technologies, including treatments for chronic wounds and diabetic ulcers.
The round brings Bioactivx's total funding to $4.9 million.
Why now? Bioactivx said it has submitted a full data package for Bioactiv® Matrix to Singapore's Health Sciences Authority for regulatory approval. It is targeting Singapore as one of its first launch markets in the fourth quarter of 2026, followed by regional expansion in 2027.
The signal: Diabetic foot ulcers carry high treatment costs and amputation risk globally, helping explain investor interest in advanced wound care. At $3 million, the round sits toward the smaller end of the funding spectrum, but reflects steady backing for early-stage medical technology emerging from Singapore's research institutions.
Read more: techinasia.com
Image credit: Generated with Gemini
